Quick Answer
Curanex Pharmaceuticals Inc reported Diluted EPS of $0.17 per share (loss) for fiscal year 2025.
Curanex Pharmaceuticals Inc Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.17 | -466.7% |
| 2024 | -$0.03 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.04 | +0.0% | — |
| June 30, 2025 | $0.00 | +100.0% | +100.0% |
| September 30, 2024 | -$0.04 | — | -100.0% |
| June 30, 2024 | -$0.02 | — | — |
- Curanex Pharmaceuticals Inc showed a decrease of -466.7% in Diluted EPS compared to the prior fiscal year.
- Over the 2024–2025 period, Curanex Pharmaceuticals Inc’s diluted eps has declined by 466.7% (from $0.03 per share (loss) to $0.17 per share (loss)).
- The most recent figure is from Curanex Pharmaceuticals Inc’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: